Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
739 studies found for:    cystic fibrosis
Show Display Options
Rank Status Study
21 Terminated Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Constipation;   Nutrition
Intervention:
22 Active, not recruiting Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls
Condition: Cystic Fibrosis
Interventions: Device: Peripheral quantitative computed tomography (pQCT);   Device: Dual X-ray absorptiometry (DXA)
23 Completed
Has Results
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
Condition: Cystic Fibrosis
Intervention: Drug: AZLI 75 mg two times a day (BID)/ three times a day (TID)
24 Completed Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.
Condition: Cystic Fibrosis
Intervention:
25 Completed
Has Results
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor 25 mg/75 mg;   Drug: Ivacaftor 75 mg/150 mg;   Drug: Ivacaftor 150 mg or 250 mg;   Drug: Placebo
26 Completed Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults
Conditions: Cystic Fibrosis;   Healthy
Intervention: Device: Comparison of two MBWN2 devices : "EasyOne Pro Lab" versus "Exhalyzer D"
27 Completed Osteopathic Treatment in Adult Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Back Pain;   Neck Pain;   Chest Pain
Interventions: Procedure: Osteopathic treatment;   Procedure: Sham Placebo;   Procedure: Usual care
28 Completed Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Intervention: Other: no intervention
29 Not yet recruiting Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Other: Lung explants;   Other: Sputum, nasal fluid and serum;   Procedure: Bronchoscopy
30 Recruiting A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
Conditions: Cystic Fibrosis;   Pediatrics
Intervention: Biological: Sputum
31 Recruiting Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
Condition: Cystic Fibrosis Lung Disease
Intervention:
32 Completed
Has Results
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor;   Drug: Placebo
33 Completed
Has Results
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
Condition: Cystic Fibrosis
Interventions: Drug: VX-770;   Drug: Placebo
34 Completed Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
Conditions: Cystic Fibrosis;   Pancreatic Insufficiency
Interventions: Drug: Liprotamase;   Drug: Placebo
35 Completed Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)
Condition: Cystic Fibrosis
Intervention: Drug: Fluticasone or placebo
36 Recruiting Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention:
37 Completed Multidose Safety and Tolerability Study of (Arikace™) for Inhalation In Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Intervention: Drug: Arikace™
38 Not yet recruiting Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Device: High-Flow, 20 LPM (via Optiflow cannula);   Device: Low FLow, 5 LPM (via Optiflow cannula)
39 Recruiting Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON;   Biological: ZENPEP;   Biological: ULTRESA;   Biological: PANCREAZE;   Biological: other non-sponsor pancreatic enzyme replacement therapy;   Other: No pancreatic enzyme replacement therapy
40 Terminated Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: Piperacillin-tazobactam combination product

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years